Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [(68)Ga]PSMA-PET-guided metastasis-directed therapy

PURPOSE: Since the success of prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging for patients with oligorecurrent prostate cancer (ORPC), it is increasingly used for radiotherapy as metastasis-directed therapy (MDT). Therefore, we developed a prognostic risk classific...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Nucl Med Mol Imaging
Autors principals: Vogel, Marco M. E., Kroeze, Stephanie G. C., Henkenberens, Christoph, Schmidt-Hegemann, Nina-Sophie, Kirste, Simon, Becker, Jessica, Burger, Irene A., Derlin, Thorsten, Bartenstein, Peter, Mix, Michael, la Fougère, Christian, Eiber, Matthias, Christiansen, Hans, Belka, Claus, Grosu, Anca L., Müller, Arndt-Christian, Guckenberger, Matthias, Combs, Stephanie E.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7396407/
https://ncbi.nlm.nih.gov/pubmed/32179961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-04760-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars